Compare Charles River Laboratories Intl. Inc (CRL) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs FTAI Aviation Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while FTAI Aviation Ltd trades at $169.97 (market cap $17.57B). The key difference: FTAI Aviation Ltd is the larger of the two by market cap, and FTAI Aviation Ltd pays a 1.17% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and FTAI Aviation Ltd for 23 Days on average.
| CRL | FTAI | |
|---|---|---|
Market Cap | $14.23B | $17.57B |
Volume | 1,176,885 | 1,905,014 |
Sector | Health | Industrials |
52-Week High | $310.77 | $310.04 |
52-Week Low | $149.93 | $152.80 |
Typical Hold Time | 33 Days | 23 Days |
Enterprise Value | $17.06B | $20.69B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298.00, down 0.77% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of -$144.34M for 2025. Analyst consensus is strongly positive with a $305.50 price target, and recent news highlights a strategic growth plan targeting 5%-7% revenue growth by 2030.
The stock's outlook is supported by strong analyst buy ratings and a clear growth strategy, but faces risks from negative profitability metrics and high valuation multiples. Investment opportunity hinges on successful execution of margin expansion and cost savings initiatives, while key risks include persistent net losses and competitive pressures in the healthcare services sector.
FTAI Aviation trades at $171.06, down 2.16% amid a bearish technical signal, with support at $169 and resistance at $173. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS estimates. Recent developments include a $500M share buyback program and a 5-year Asia-Pacific maintenance deal with GMF, signaling strategic growth initiatives.
The outlook is mixed: robust analyst consensus (100% buy ratings, $321.25 price target) and shareholder-friendly actions support upside, but consecutive earnings misses, negative operating cash flow, and high valuation ratios (P/E 37.35) pose risks. Investors should weigh growth in aerospace segments against execution challenges and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
